Study to Evaluate OMR-12200 as a Negative Contrast Agent for Magnetic Resonance Cholangio-Pancreatography

Trial Profile

Study to Evaluate OMR-12200 as a Negative Contrast Agent for Magnetic Resonance Cholangio-Pancreatography

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Ferric ammonium citrate (Primary)
  • Indications Gastrointestinal disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 20 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top